<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">APY</journal-id>
<journal-id journal-id-type="hwp">spapy</journal-id>
<journal-title>Australasian Psychiatry</journal-title>
<issn pub-type="ppub">1039-8562</issn>
<issn pub-type="epub">1440-1665</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1039856212447861</article-id>
<article-id pub-id-type="publisher-id">10.1177_1039856212447861</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correspondence</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolic syndrome in an adolescent psychiatric unit</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Dullur</surname><given-names>Pravin</given-names></name>
<aff id="aff1-1039856212447861">Campbelltown, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Eapen</surname><given-names>Valsamma</given-names></name>
<aff id="aff2-1039856212447861">Sydney, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Trapolini</surname><given-names>Tania</given-names></name>
<aff id="aff3-1039856212447861">Sydney, Australia</aff>
</contrib>
</contrib-group>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>5</issue>
<fpage>444</fpage>
<lpage>445</lpage>
<permissions>
<copyright-statement>© 2012 The Royal Australian and New Zealand College of Psychiatrists</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Dear Sir,</p>
<p>Metabolic syndrome (MS) is a constellation of abnormalities conferring a higher risk of cardioendocrine adverse events.<sup><xref ref-type="bibr" rid="bibr1-1039856212447861">1</xref>,<xref ref-type="bibr" rid="bibr2-1039856212447861">2</xref></sup> MS as defined by the Cook criteria<sup><xref ref-type="bibr" rid="bibr1-1039856212447861">1</xref></sup> includes at least three of the following:</p>
<list id="list1-1039856212447861" list-type="simple">
<list-item><p>1) triglyceride level ≥ 1.7 mmol/l;</p></list-item>
<list-item><p>2) high-density lipoprotein (HDL) &lt; 1.03 mmol/l;</p></list-item>
<list-item><p>3) abdominal obesity (waist circumference ≥ 90th percentile for age and gender);</p></list-item>
<list-item><p>4) fasting blood sugar ≥ 6.1 mmol/l; and</p></list-item>
<list-item><p>5) blood pressure (BP) ≥ 90th percentile for age and gender.</p></list-item>
</list>
<p>Correll’s ‘at risk’ criteria<sup><xref ref-type="bibr" rid="bibr2-1039856212447861">2</xref></sup> include at least one of the following:</p>
<list id="list2-1039856212447861" list-type="simple">
<list-item><p>1) ≥ 85th body mass index (BMI) percentile and one of:<list id="list3-1039856212447861" list-type="simple">
<list-item><p>a) hypertension (BP &gt; 90th percentile);</p></list-item>
<list-item><p>b) fasting cholesterol ≥ 5.17 mmol/l;</p></list-item>
<list-item><p>c) low-density lipoprotein (LDL) &gt; 3.36 mmol/l;</p></list-item>
<list-item><p>d) HDL &lt; 1.03 mmol/l;</p></list-item>
<list-item><p>e) triglyceride ≥ 1.7 mmol/l; and</p></list-item>
<list-item><p>f) fasting blood sugar ≥ 6.1 mmol/l; and</p></list-item>
</list></p></list-item>
<list-item><p>2) ≥ 95th BMI percentile.</p></list-item>
</list>
<p>Reports of significant metabolic abnormalities in adolescents on second-generation antipsychotics (SGAs) are now emerging.<sup><xref ref-type="bibr" rid="bibr3-1039856212447861">3</xref><xref ref-type="bibr" rid="bibr4-1039856212447861"/>–<xref ref-type="bibr" rid="bibr5-1039856212447861">5</xref></sup> We report findings on weight and metabolic abnormalities among patients admitted to an adolescent psychiatric inpatient unit.</p>
<p>Fifty consecutive inpatients aged 13–17 (mean age 15.75 years; 78% female) were studied. Psychiatric diagnoses included major depressive disorder (50%), bipolar affective disorder (16%), psychotic disorders (10%), nicotine use (40%) and borderline personality traits (36%). A sedentary lifestyle was reported in 75%.</p>
<p>Thirty-three patients (66%) were exposed to SGAs (mean duration: 6.6 months). The mean BMI was 26.95 kg/m<sup>2</sup>. This compares similarly to that of Patel and colleagues,<sup><xref ref-type="bibr" rid="bibr4-1039856212447861">4</xref></sup> who reported this figure as 27.6 kg/m<sup>2</sup>. The prevalence of being overweight (BMI = 85th–95th percentile) or obesity (BMI &gt; 95th percentile) was 46.6%. Previous studies have reported figures between 31% and 68%.<sup><xref ref-type="bibr" rid="bibr4-1039856212447861">4</xref><xref ref-type="bibr" rid="bibr5-1039856212447861"/>–<xref ref-type="bibr" rid="bibr6-1039856212447861">6</xref></sup> Ten per cent met a full diagnosis of Cook’s positive MS, while 40% satisfied at least one of the criteria. Of the obese/overweight patients on SGAs, 42.9% had elevated triglyceride levels. Rates in other studies<sup><xref ref-type="bibr" rid="bibr4-1039856212447861">4</xref></sup> were 51%. Similarly, 71.4% of patients on SGAs who were obese/overweight were ‘at risk’. Thirty-six per cent had 1–2 of Cook’s criteria, while 48% had at least one abnormality as defined by Correll’s criteria. The most common metabolic abnormality was elevated triglycerides. Psychological distress was reported in 40%. The symptoms included low mood, crying, social isolation, low self-esteem, poor body image, sleep problems, self-blame, guilt, anger and irritability.</p>
<p>The high prevalence of metabolic abnormalities is in keeping with previous studies and occurred despite the lower usage of olanzapine and clozapine. The small sample size precluded comparisons between individual antipsychotics. The impact of diet and sedentary lifestyle could not be assessed.</p>
<p>Papers regarding suggestions on monitoring metabolic abnormalities<sup><xref ref-type="bibr" rid="bibr5-1039856212447861">5</xref>,<xref ref-type="bibr" rid="bibr7-1039856212447861">7</xref></sup> are slowly emerging. A recent survey demonstrated that while child psychiatrists are concerned regarding metabolic side effects, their monitoring practices do not reflect the concern.<sup><xref ref-type="bibr" rid="bibr8-1039856212447861">8</xref></sup> This paper highlights both the high prevalence of metabolic abnormalities in adolescents and the significant psychological distress associated with it. As such, we strongly support and emphasise previous calls<sup><xref ref-type="bibr" rid="bibr8-1039856212447861">8</xref></sup> for the need to systematically monitor and intervene for such adolescents.</p>
<p>To the best of our knowledge, this is the first study assessing metabolic abnormalities among an Australian sample of adolescent inpatients treated with SGAs. Future research will need larger samples and should include prospective studies.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1039856212447861">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cook</surname><given-names>S</given-names></name>
<name><surname>Weitzman</surname><given-names>M</given-names></name>
<name><surname>Auinger</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey 1988–1994</article-title>. <source>Archives of Pediatrics &amp; Adolescent Medicine</source> <year>2003</year>; <volume>157</volume>: <fpage>821</fpage>–<lpage>827</lpage>.</citation>
</ref>
<ref id="bibr2-1039856212447861">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correll</surname><given-names>CU</given-names></name>
<name><surname>Carlson</surname><given-names>HE</given-names></name>
</person-group>. <article-title>Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents</article-title>. <source>Journal of the American Academy of Child and Adolescent Psychiatry</source> <year>2006</year>; <volume>45</volume>: <fpage>771</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr3-1039856212447861">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correll</surname><given-names>CU</given-names></name>
</person-group>. <article-title>Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials</article-title>. <source>Journal of the American Academy of Child and Adolescent Psychiatry</source> <year>2007</year>; <volume>46</volume>: <fpage>687</fpage>–<lpage>700</lpage>.</citation>
</ref>
<ref id="bibr4-1039856212447861">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>NC</given-names></name>
<name><surname>Hariparsad</surname><given-names>M</given-names></name>
<name><surname>Matias-Akthar</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics</article-title>. <source>Journal of Child and Adolescent Psychopharmacology</source> <year>2007</year>; <volume>17</volume>: <fpage>303</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr5-1039856212447861">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panagiotopoulos</surname><given-names>C</given-names></name>
<name><surname>Ronsley</surname><given-names>R</given-names></name>
<name><surname>Davidson</surname><given-names>J</given-names></name>
</person-group>. <article-title>Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications</article-title>. <source>Canadian Journal of Psychiatry</source> <year>2009</year>; <volume>54</volume>:<fpage>743</fpage>–<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr6-1039856212447861">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hedley</surname><given-names>AA</given-names></name>
<name><surname>Ogden</surname><given-names>CL</given-names></name>
<name><surname>Johnson</surname><given-names>CL</given-names></name><etal/>
</person-group>. <article-title>Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002</article-title>. <source>JAMA: the Journal of the American Medical Association</source> <year>2004</year>; <volume>291</volume>: <fpage>2847</fpage>–<lpage>2850</lpage>.</citation>
</ref>
<ref id="bibr7-1039856212447861">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hetrick</surname><given-names>S</given-names></name>
<name><surname>Alvarez-Jiménez</surname><given-names>M</given-names></name>
<name><surname>Parker</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic</article-title>. <source>Australasian Psychiatry</source> <year>2010</year>; <volume>18</volume>: <fpage>451</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr8-1039856212447861">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>G</given-names></name>
<name><surname>DeLaroche</surname><given-names>A</given-names></name>
<name><surname>Soh</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Side effects of second-generation antipsychotics: the experience, views and monitoring practices of Australian child psychiatrists</article-title>. <source>Australasian Psychiatry</source> <year>2008</year>; <volume>16</volume>: <fpage>253</fpage>–<lpage>262</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>